| Pathological outcomes of candidates for active surveillance of prostate cancer SL Conti, M Dall'Era, V Fradet, JE Cowan, J Simko, PR Carroll The Journal of urology 181 (4), 1628-1634, 2009 | 208 | 2009 |
| Dietary omega-3 fatty acids, cyclooxygenase-2 genetic variation, and aggressive prostate cancer risk V Fradet, I Cheng, G Casey, JS Witte Clinical Cancer Research 15 (7), 2559-2566, 2009 | 183 | 2009 |
| Nuclear factor-κB nuclear localization is predictive of biochemical recurrence in patients with positive margin prostate cancer V Fradet, L Lessard, LR Bégin, P Karakiewicz, AMM Masson, F Saad Clinical cancer research 10 (24), 8460-8464, 2004 | 168 | 2004 |
| Prostate cancer managed with active surveillance: role of anatomic MR imaging and MR spectroscopic imaging V Fradet, J Kurhanewicz, JE Cowan, A Karl, FV Coakley, K Shinohara, ... Radiology 256 (1), 176-183, 2010 | 145 | 2010 |
| Intermittent vs continuous androgen deprivation therapy for prostate cancer: a systematic review and meta-analysis S Magnan, R Zarychanski, L Pilote, L Bernier, M Shemilt, E Vigneault, ... JAMA oncology 1 (9), 1261-1269, 2015 | 144 | 2015 |
| Assessing cancer risk on novel 29 MHz micro-ultrasound images of the prostate: creation of the micro-ultrasound protocol for prostate risk identification S Ghai, G Eure, V Fradet, ME Hyndman, T McGrath, B Wodlinger, ... The Journal of urology 196 (2), 562-569, 2016 | 131 | 2016 |
| Geographic distribution of urologists throughout the United States using a county level approach AY Odisho, V Fradet, MR Cooperberg, AE Ahmad, PR Carroll The Journal of urology 181 (2), 760-766, 2009 | 107 | 2009 |
| The impact of solitary and multiple positive surgical margins on hard clinical end points in 1712 adjuvant treatment–naive pT2–4 N0 radical prostatectomy patients J Mauermann, V Fradet, L Lacombe, T Dujardin, R Tiguert, B Tetu, ... European urology 64 (1), 19-25, 2013 | 99 | 2013 |
| Urologist density and county-level urologic cancer mortality AY Odisho, MR Cooperberg, V Fradet, AE Ahmad, PR Carroll Journal of Clinical Oncology 28 (15), 2499-2504, 2010 | 96 | 2010 |
| Cardiovascular risk in men with prostate cancer: insights from the RADICAL PC study DP Leong, V Fradet, B Shayegan, E Duceppe, R Siemens, T Niazi, L Klotz, ... The Journal of urology 203 (6), 1109-1116, 2020 | 86 | 2020 |
| Prospective assessment of malnutrition in urologic patients A Karl, P Rittler, A Buchner, V Fradet, R Speer, S Walther, GC Stief Urology 73 (5), 1072-1076, 2009 | 84 | 2009 |
| Green tea for ovarian cancer prevention and treatment: a systematic review of the in vitro, in vivo and epidemiological studies D Trudel, DP Labbé, I Bairati, V Fradet, L Bazinet, B Têtu Gynecologic Oncology 126 (3), 491-498, 2012 | 65 | 2012 |
| FDG-PET/CT for pre-operative staging and prognostic stratification of patients with high-grade prostate cancer at biopsy JM Beauregard, AC Blouin, V Fradet, A Caron, Y Fradet, C Lemay, ... Cancer Imaging 15, 1-10, 2015 | 58 | 2015 |
| Risk factors for bladder cancer recurrence after nephroureterectomy for upper tract urothelial tumors: results from the Canadian Upper Tract Collaboration V Fradet, J Mauermann, W Kassouf, R Rendon, N Jacobsen, A Fairey, ... Urologic Oncology: Seminars and Original Investigations 32 (6), 839-845, 2014 | 56 | 2014 |
| ω–3 Fatty Acids, Genetic Variants in COX-2 and Prostate Cancer AC Reese, V Fradet, JS Witte Lifestyle Genomics 2 (3), 149-158, 2009 | 55 | 2009 |
| The 2002 AJCC pT2 substages confer no prognostic information on the rate of biochemical recurrence after radical prostatectomy FKH Chun, A Briganti, T Lebeau, V Fradet, T Steuber, J Walz, T Schlomm, ... European urology 49 (2), 273-279, 2006 | 53 | 2006 |
| High level of mature tumor-infiltrating dendritic cells predicts progression to muscle invasion in bladder cancer C Ayari, H LaRue, H Hovington, A Caron, A Bergeron, B Têtu, V Fradet, ... Human pathology 44 (8), 1630-1637, 2013 | 52 | 2013 |
| SRD5A polymorphisms and biochemical failure after radical prostatectomy E Audet-Walsh, J Bellemare, G Nadeau, L Lacombe, Y Fradet, V Fradet, ... European urology 60 (6), 1226-1234, 2011 | 52 | 2011 |
| Prostatic and dietary omega-3 fatty acids and prostate cancer progression during active surveillance X Moreel, J Allaire, C Léger, A Caron, MÈ Labonté, B Lamarche, P Julien, ... Cancer prevention research 7 (7), 766-776, 2014 | 46 | 2014 |
| The impact of germline genetic variations in hydroxysteroid (17-beta) dehydrogenases on prostate cancer outcomes after prostatectomy E Audet-Walsh, J Bellemare, L Lacombe, Y Fradet, V Fradet, P Douville, ... European urology 62 (1), 88-96, 2012 | 42 | 2012 |
Yves FradetUniversité Laval在 crhdq.ulaval.ca 的电子邮件经过验证
